Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
复制标题
DOI：
10.1371/journal.pone.0029868
复制
发表时间：
2012-01-18
期刊：
影响因子：
3.7
通讯作者：
Hansson, Oskar
中科院分区：
文献类型：
--
作者：
Bjorkqvist, Maria;Ohlsson, Mattias;Hansson, Oskar
迫切需要血浆中的生物标志物来识别阿尔茨海默病（AD）。先前已经表明，18种血浆蛋白的特征可以在痴呆前和痴呆阶段期间鉴定AD（Ray等人，Nature Medicine，2007）。我们定量了174名对照、142名AD患者和88名其他痴呆患者血浆中相同的18种蛋白质。这些蛋白质中只有三种（EGF、PDG-BB和MIP-1 δ）在对照和AD之间的血浆中显著不同。这18种蛋白质可以将AD患者与诊断精确度较低的对照区分开（ROC曲线下面积为63%）。此外，他们无法区分AD和其他痴呆症。总之，在探索性生物标志物研究中，结果的独立验证很重要。
There is an urgent need for biomarkers in plasma to identify Alzheimer's disease (AD). It has previously been shown that a signature of 18 plasma proteins can identify AD during pre-dementia and dementia stages (Ray et al, Nature Medicine, 2007). We quantified the same 18 proteins in plasma from 174 controls, 142 patients with AD, and 88 patients with other dementias. Only three of these proteins (EGF, PDG-BB and MIP-1 delta) differed significantly in plasma between controls and AD. The 18 proteins could classify patients with AD from controls with low diagnostic precision (area under the ROC curve was 63%). Moreover, they could not distinguish AD from other dementias. In conclusion, independent validation of results is important in explorative biomarker studies.